
Patrick K Campbell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3448125/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Development of BRAFV600E-positive acute myeloid leukemia in a patient on long-term dabrafenib for multisystem LCH. Blood Advances, 2022, , .	5.2	5
2	Haemophagocytic lymphohistiocytosis restricted to the central nervous system. Archives of Disease in Childhood, 2021, 106, 527-527.	1.9	1
3	Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies. Cancer, 2021, 127, 2074-2082.	4.1	2
4	Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1277-1303.	4.9	26
5	Dasatinib induces a dramatic response in a child with refractory juvenile xanthogranuloma with a novel MRC1-PDGFRB fusion. Blood Advances, 2020, 4, 2991-2995.	5.2	10
6	Neuroinflammatory Disease as an Isolated Manifestation of Hemophagocytic Lymphohistiocytosis. Journal of Clinical Immunology, 2020, 40, 901-916.	3.8	33
7	Optimizing Drug-Drug Interaction Alerts Using a Multidimensional Approach. Pediatrics, 2019, 143, .	2.1	14
8	CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCHâ€associated neurodegeneration and mass lesions. Cancer, 2018, 124, 2607-2620.	4.1	73
9	Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	19
10	Clinical Outcomes and Molecular Responses in Children with Langerhans Cell Histiocytosis Treated with MAPK Pathway Inhibitors. Blood, 2018, 132, 3684-3684.	1.4	2
11	Hemophagocytic Lymphohistiocytosis and Progressive Disseminated Histoplasmosis. Emerging Infectious Diseases, 2016, 22, 1119-1121.	4.3	14
12	The Role of Leukapheresis in the Current Management of Hyperleukocytosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia. Pediatric Blood and Cancer, 2016, 63, 1546-1551.	1.5	29
13	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	9.4	372
14	a Phase I Trial of Bendamustine in Combination with Clofarabine and Etoposide in Pediatric Patients with Relapsed or Refractory Hematologic Malignancies. Blood, 2016, 128, 1628-1628.	1.4	1
15	Utility of Early Screening Magnetic Resonance Imaging for Extensive Hip Osteonecrosis in Pediatric Patients Treated With Glucocorticoids. Journal of Clinical Oncology, 2015, 33, 610-615.	1.6	56
16	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Blood, 2015, 126, 481-481.	1.4	0
17	Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase. Cancer Chemotherapy and Pharmacology, 2014, 73, 1307-1313.	2.3	20
18	Unraveling the Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms through Whole Exome Sequencing. Blood, 2014, 124, 1887-1887.	1.4	1

PATRICK K CAMPBELL

#	Article	IF	CITATIONS
19	Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia. Cancer, 2013, 119, 2061-2066.	4.1	27
20	Clofarabine salvage therapy for refractory highâ€risk langerhans cell histiocytosis. Pediatric Blood and Cancer, 2013, 60, E19-22.	1.5	34
21	Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia. Leukemia Research, 2011, 35, 1321-1329.	0.8	21
22	Loss of Â-tubulin polyglutamylation in ROSA22 mice is associated with abnormal targeting of KIF1A and modulated synaptic function. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3213-3218.	7.1	202
23	Mutation of a Novel Gene Results in Abnormal Development of Spermatid Flagella, Loss of Intermale Aggression and Reduced Body Fat in Mice. Genetics, 2002, 162, 307-320.	2.9	64